CCEL - שווי פעילות לרווח לפני ריבית, מסים ופחת Cryo-Cell International, Inc.

Cryo-Cell International (CCEL) generates revenue from long-term biobanking fees, which ensures a predictable cash flow and eliminates liquidity shortages. The company's environmental development vector relies on upgrading cryochamber insulation and transitioning to green energy. The current EV/EBITDA ratio stands at 28.78. The asset's price trajectory shown below confirms the effectiveness of management's strategy to implement GMP standards and expand cell therapy.

Fundamental asset screening requires a precise determination of business value relative to its operating profit before depreciation, interest, and taxes. By analyzing the EV/EBITDA multiple, an investor assesses the real market weight of Cryo-Cell International (CCEL) accounting for debt, which is further supported by the stability of costs for retaining highly qualified biochemists and the absence of labor shortages.